BioTuesdays

Journal of Cancer paper identifies TRPV6 as a promising drug target in numerous cancers, including breast, ovarian, prostate and pancreatic cancer

Soricimed

The peer-reviewed Journal of Cancer published a positive review of TRPV6 as a cancer therapy target, supporting the potential of closely-held Soricimed’s lead drug candidate, SOR-C13.

TRPV6 plays a role in increasing intracellular calcium and initiating downstream signalling pathways that increase cell proliferation and metastasis, while inhibiting apoptosis, or cell death. The review identifies TRPV6 as a promising drug target in a number of cancers including breast, ovarian, prostate and pancreatic cancer.

Soricimed is developing SOR-C13, the first TRPV6 inhibitor to enter clinical trials, which demonstrated safety and anticancer activity in a Phase 1 clinical trial in late-stage solid tumor cancers. SOR-C13 is currently being tested in a Phase 1b, investigator initiated trial at MD Anderson Cancer Center for the treatment of late-stage pancreatic cancer.

“This article compiles everything we know about TRPV6 – how it works, its mechanism of action as an oncochannel and what controls its gene expression,” Jack Stewart, the publication’s author and Soricimed’s cofounder and CSO, said in a statement.

“In addition to demonstrating TRPV6 as a useful target for solid cancers, this publication outlines how we can exploit TRPV6’s overexpression to treat several cancer types,” he added.

The publication, entitled “TRPV6 as A Target for Cancer Therapy,” is available here.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.